

IACH 2020 Scientific Program

Meeting co-chairs: Mohamad Mohty, Arnon Nagler, Jordi Sierra

Local co-chairs: Didier Blaise, Thomas Cluzeau

Thursday, October 1, 2020	
14:30-15:50	Session 1: The 2020 highlights in ...
	<i>Opening remarks: Mohamad Mohty, France & Arnon Nagler, Israel</i>
	... high-risk AML: Arnon Nagler, Israel
	... CML: François Guilhot, France
	... MDS: Thomas Cluzeau, France
15:50-17:00	Session 2: Advances in AML biology
	Role of NPM1 mutation: Brunangelo Falini, Italy
	Impact of microbiota modulation: Florent Malard, France
	Panel discussion
17:00-18:15	Session 3: The hard to treat patients
	Relapsed/refractory B-ALL: Dieter Hoelzer, Germany
	Relapsed/refractory T-ALL: Eolia Brissot, France
	Transplant for refractory AML: Mohamad Mohty, France
	Panel discussion
18:15-19:00	Session 4: H.J. Khoury award
	H.J. Khoury award presentation
	PML, an unexpected effector of therapy response in APL and other malignancies: Hugues de Thé, France

Friday, October 2, 2020	
08:30-10:10	Session 5: Remission and post-remission therapy in high-risk acute leukemia
	Induction therapy in AML: Michael Loschi, France
	Allo-transplant in AML: Jordi Sierra, Spain
	Autologous transplantation in AML: Norbert-Claude Gorin, France
	Allo-transplant in ALL: Sebastian Giebel, Poland
	Panel discussion
10:10-11:40	Industry Sponsored Symposium on VOD
11:40-13:20	Session 6: CAR-T cells in ALL
	Recent results in children: André Baruchel, France
	Recent results in adults: Christian Chabannon, France
	Experience from China: He Huang, China
	Management of toxicities: Bipin Savani, USA
13:20-14:05	Lunch Break – Industry hosted Roundtable discussion
14:05-16:10	Session 7: Management of elderly leukemia
	Chairs: <i>TBA</i>
	AML: Farhad Ravandi, USA
	Transplant for elderly leukemia: Didier Blaise, France
	Supportive care: Bipin Savani, USA
	Transplant for MDS: Ibrahim Yakoub-Agha, France
	Panel discussion
16:10-17:00	Industry Sponsored Symposium on AML

Saturday, October 3, 2020	
08:30-9:50	Session 8: Management of rare leukemias
	Plasmacytoid dendritic cell leukemia: Naveen Pemmaraju, USA
	ATL and HTLV-related disorders: Ali Bazarbachi, Lebanon
	Acute promyelocytic leukemia: Miguel Sanz, Spain

Saturday, October 3, 2020

9:50-11:20	Session 9: Novel drugs in leukemia
	BTK inhibitors: Gianluca Gaidano , Italy
	Antibody-drug conjugates: Norbert Vey , France
	BCL-2 inhibitors: Thomas Prebet , USA
	Panel discussion
11:20-13:00	Closing lectures
	Advances in ALL therapy: Hagop Kantarjian , USA
	Flt3 inhibitors in AML: Richard Stone , USA
	Novel drugs development, evaluation and access: Jean-Luc Harousseau , France
	Closing remarks